NRX Pharmaceuticals, Inc. Operating Leases, Rent Expense
NRX Pharmaceuticals, Inc. (NRXP) reported Operating Leases, Rent Expense of $100.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2022-08-15
- NRX Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2022-06-30 was $100.00K, a 0.00% change year-over-year.
- NRX Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2022-03-31 was $100.00K, a 0.00% change year-over-year.
- NRX Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2021-12-31 was $35.45K, a 47.82% decline year-over-year.
- NRX Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2021-09-30 was $9.16K, a 35.36% decline year-over-year.
- NRX Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2021 was $100.00K, a 0.00% change from fiscal 2020.
- NRX Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2020 was $100.00K.
- NRX Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2018 was $75.00K.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 3 month as first filed | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 6 month as first filed | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|---|
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-15 | $100.00K 10-Q · filed 2022-08-15 | $235.44K derived: sum of 3 quarters · filed 2022-08-15 | $244.61K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-16 | $135.44K derived: sum of 2 quarters · filed 2022-05-16 | $144.61K derived: sum of 3 quarters · filed 2022-08-12 | $244.61K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-12-31 | $35.45K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $44.61K derived: sum of 2 quarters · filed 2022-08-12 | $144.61K derived: sum of 3 quarters · filed 2022-08-15 | $100.00K 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $9.16K 10-Q/A · filed 2022-08-12 | $109.16K derived: sum of 2 quarters · filed 2022-08-15 | $64.56K 10-Q/A · filed 2022-08-12 | $277.09K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-15 | $48.78K 10-Q · filed 2021-08-16 | $100.00K 10-Q · filed 2022-08-15 | $55.39K 10-Q · filed 2021-08-16 | $267.92K derived: sum of 3 quarters · filed 2022-08-15 | $282.10K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-16 | $167.92K derived: sum of 2 quarters · filed 2022-05-16 | $182.10K derived: sum of 3 quarters · filed 2022-08-12 | $191.19K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-12-31 | $67.92K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $82.10K derived: sum of 2 quarters · filed 2022-08-12 | $91.19K derived: sum of 3 quarters · filed 2022-08-12 | $100.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $14.17K 10-Q/A · filed 2022-08-12 | $23.26K derived: sum of 2 quarters · filed 2022-08-12 | $32.08K 10-Q/A · filed 2022-08-12 | |||
| 2020-06-30 | $9.09K 10-Q/A · filed 2022-08-12 | $17.90K 10-Q/A · filed 2022-08-12 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $15.00K derived: sum of 2 quarters · filed 2020-03-30 | $45.00K derived: sum of 3 quarters · filed 2020-03-30 | $75.00K 10-K · filed 2020-03-30 | ||
| 2018-09-30 | $15.00K 10-Q · filed 2018-11-08 | $45.00K derived: sum of 2 quarters · filed 2018-11-08 | $75.00K 10-Q · filed 2018-11-08 | $90.00K derived: sum of 4 quarters · filed 2019-03-15 | ||
| 2018-06-30 | $30.00K 10-Q · filed 2018-08-08 | $60.00K 10-Q · filed 2018-08-08 | $75.00K derived: sum of 3 quarters · filed 2019-03-15 | |||
| 2018-03-31 | $30.00K 10-Q · filed 2018-05-15 | $45.00K derived: sum of 2 quarters · filed 2019-03-15 | ||||
| 2017-12-31 | $15.00K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |